Tracing of intracellular pH in cancer cells in response to Taxol treatment

Cell Cycle. 2021 Aug;20(16):1540-1551. doi: 10.1080/15384101.2021.1949106. Epub 2021 Jul 25.

Abstract

Genetically encoded pH-sensors are the promising instrument for intracellular pH (pHi) registration. In tumor tissue the reversed pH gradient is known to be the important hallmark of cancer and regulator of tumor response on chemotherapy. However the effect of chemotherapeutic drugs on the pHi of tumor cells is largely unknown. Here we using genetically encoded ratiometric pH-sensor SypHer2 were able to monitor pHi in vitro in cell monolayer and tumor spheroids and in vivo in tumor xenografts. In tumor cell monolayer different pHi dynamic was revealed in the dying cell and division-arrested surviving cells. The treatment effect of taxol varied in monolayer and tumor spheroids and pHi changes were able to reflect these difference. The tend to pHi decrease in respect to taxol in vivo matched with results obtained for the cell monolayer. Also in both cases the cell cycle-arrest was the main treatment effect in contrast to tumor spheroid, where the cell death was the primary result. These findings elucidate the significance of pHi in the mechanisms of taxol action on cervical cancer cells and will be valuable for development of new approaches for cancer treatment.

Keywords: Taxol; cancer cell; chemotherapy; intracellular pH; paclitaxel; response to chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Biosensing Techniques*
  • Cell Proliferation / drug effects*
  • Female
  • HeLa Cells
  • Humans
  • Hydrogen-Ion Concentration
  • Luminescent Proteins / biosynthesis
  • Luminescent Proteins / genetics
  • Mice
  • Mice, Nude
  • Microscopy, Fluorescence*
  • Paclitaxel / pharmacology*
  • Time Factors
  • Tumor Burden
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / genetics
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / pathology
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents, Phytogenic
  • Luminescent Proteins
  • Paclitaxel

Grants and funding

This work was supported by the Russian Foundation for Basic Research [19-32-90139].